$CLVS Sometimes offerings work out for everyone in good time...wait for earnings updates with prostate sales in August and Lucitanib Opdivo data at ESMO in September. Lucitanib is the game changer for Clovis. It’s only an $85m raise and think about if the mkt turns lower in the summer into the fall - May be hard to raise in COVID marketplace. Examples of successful offerings below: streetinsider.com/dr/news.p... $150m Secondary at $33 - bought for $85 5 months later after inclisiran data (also lots of convertible debt) prnewswire.com/news-release... $225m Secondary at $10.75 - Bought for $48 22 months later after combo data
  • 11
11 Likes